| 许 英,杨 洁,李 娜,安晓娟,黄 兵,张 霞.特罗凯靶向治疗联合培美曲塞和顺铂对非小细胞肺癌患者血清肿瘤标志物、免疫球蛋白和T淋巴细胞亚群的影响[J].现代生物医学进展英文版,2021,(17):3264-3267. |
| 特罗凯靶向治疗联合培美曲塞和顺铂对非小细胞肺癌患者血清肿瘤标志物、免疫球蛋白和T淋巴细胞亚群的影响 |
| Effects of Tarceva Targeted Therapy Combined with Pemetrexed and Cisplatin on Serum Tumor Markers, Immunoglobulin and T-lymphocyte Subsets in Patients with Non-small Cell Lung Cancer |
| Received:February 05, 2021 Revised:February 27, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.17.014 |
| 中文关键词: 特罗凯靶向治疗 培美曲塞 顺铂 非小细胞肺癌 肿瘤标志物 免疫球蛋白 T淋巴细胞亚群 |
| 英文关键词: Tarceva targeted therapy Pemetrexed Cisplatin Non-small cell lung cancer Tumor markers Immunoglobulin T lymphocyte subsets |
| 基金项目:江苏省卫生厅预防医学科研项目（Y2013067） |
|
| Hits: 856 |
| Download times: 550 |
| 中文摘要: |
| 摘要 目的：探讨特罗凯靶向治疗联合培美曲塞和顺铂对非小细胞肺癌（NSCLC）患者血清肿瘤标志物、免疫球蛋白和T淋巴细胞亚群的影响。方法：选取2018年2月~2020年2月期间我院接收的NSCLC患者80例，采用抽签法分为对照组、观察组两组，各40例。对照组给予培美曲塞和顺铂化疗方案治疗，观察组在对照组基础上联合特罗凯靶向治疗，对比两组总有效率、血清肿瘤标志物、免疫球蛋白、T淋巴细胞亚群及不良反应发生率。结果：对比两组不良反应无差异（P>0.05）。治疗3个疗程后，对照组、观察组的临床总有效率分别为37.50%、60.00%，观察组的总有效率高于对照组（P<0.05）。治疗3个疗程，观察组CD3+、CD4+、CD4+/CD8+高于对照组，CD8+低于对照组（P<0.05）。治疗3个疗程，观察组免疫球蛋白G（IgG）、免疫球蛋白A（IgA）、免疫球蛋白M（IgM）高于对照组（P<0.05）。治疗3个疗程，观察组细胞角蛋白19片段（CYFRA21-1）、糖类抗原50（CA50）、癌胚抗原（CEA）低于对照组（P<0.05）。结论：特罗凯靶向治疗联合培美曲塞和顺铂治疗NSCLC患者，疗效较好，可能与该方案可降低患者血清肿瘤标志物含量、调节免疫应答等因素有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of tarceva targeted therapy combined with pemetrexed and cisplatin on serum tumor markers, immunoglobulin and T lymphocyte subsets in patients with non-small cell lung cancer (NSCLC). Methods: 80 NSCLC patients who were admitted to our hospital from February 2018 to February 2020 were selected, they were divided into two groups as control group and observation group by drawing lots, 40 cases in each group. The control group was treated with pemetrexed and cisplatin chemotherapy, while the observation group was treated with tarceva targeted therapy on the basis of the control group. The total effective rate, serum tumor markers, immunoglobulin, T lymphocyte subsets and incidence of adverse reactions between two groups were compared. Results: There was no difference in adverse reactions between two groups(P>0.05). After 3 courses of treatment, the clinical total effective rates of the control group and the observation group were 37.50% and 60.00%, and the total effective rate of observation group was higher than that of control group (P<0.05). After 3 courses of treatment, CD3+, CD4+, CD4+/CD8+ in the observation group were higher than those of control group, CD8+ in observation group was lower than that in control group(P<0.05). After 3 courses of treatment, the levels of immunoglobulin G(IgG), immunoglobulin A (IGA), immunoglobulin M (IgM) in the observation group were higher than those of control group(P<0.05). After 3 courses of treatment, Cytokeratin-19-fragment(CYFRA21-1), Carbohydrate antigen 50(CA50), Carcinoembryonic antigen(CEA) in observation group were lower than those in control group(P<0.05). Conclusion: Tarceva targeted therapy combined with pemetrexed and cisplatin is effective in the treatment of NSCLC patients, the curative effect is good, which may be related to the reduction of serum tumor markers and the regulation of immune response. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
